Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**TFC-1394** is an investigational depigmenting small molecule from Sirona Biochem's carbohydrate-chemistry-derived compound library. Public disclosures identify it as a compound related to TFC-1067 and being retained for therapeutic development in **melasma** and potentially for use in regions with different regulatory requirements. Its precise chemical structure, dosage form, route, and definitive molecular target have not been publicly disclosed in the sources reviewed. Based on the company's positioning of TFC-1394 alongside its skin-lightening program, it appears to be a melanogenesis-modulating candidate intended to reduce hyperpigmentation, but a target-level mechanism of action cannot be stated with confidence from available evidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TFC-1394.